Medtronic PLC (MDT) Position Reduced by Castleark Management LLC
Castleark Management LLC lowered its position in shares of Medtronic PLC (NYSE:MDT) by 35.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,471 shares of the medical technology company’s stock after selling 72,653 shares during the period. Castleark Management LLC’s holdings in Medtronic PLC were worth $11,668,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of MDT. Parkside Financial Bank & Trust lifted its stake in Medtronic PLC by 22.4% during the second quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock worth $102,000 after purchasing an additional 210 shares during the last quarter. BDO Wealth Advisors LLC bought a new stake in Medtronic PLC during the second quarter worth about $103,000. Motco lifted its stake in Medtronic PLC by 8.7% during the second quarter. Motco now owns 1,239 shares of the medical technology company’s stock worth $110,000 after purchasing an additional 99 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in Medtronic PLC by 21.5% during the second quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 290 shares during the last quarter. Finally, Israel Discount Bank of New York bought a new stake in Medtronic PLC during the first quarter worth about $117,000. 81.14% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have issued reports on MDT. Jefferies Group LLC reaffirmed a “buy” rating and set a $99.00 price target on shares of Medtronic PLC in a research note on Thursday. Zacks Investment Research raised Medtronic PLC from a “sell” rating to a “hold” rating in a research note on Thursday. Northland Securities reissued a “hold” rating and issued a $80.00 target price on shares of Medtronic PLC in a research note on Wednesday. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $94.00 target price on shares of Medtronic PLC in a research note on Wednesday. Finally, Stifel Nicolaus boosted their target price on Medtronic PLC from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Medtronic PLC presently has an average rating of “Hold” and a consensus target price of $88.02.
Medtronic PLC (MDT) opened at $83.21 on Friday. Medtronic PLC has a twelve month low of $69.35 and a twelve month high of $89.72. The stock has a market capitalization of $111,454.77, a PE ratio of 17.75, a P/E/G ratio of 2.17 and a beta of 1.00. The company has a current ratio of 2.40, a quick ratio of 1.40 and a debt-to-equity ratio of 0.50.
Medtronic PLC (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.08. Medtronic PLC had a return on equity of 12.63% and a net margin of 16.93%. The company had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $7.05 billion. During the same quarter in the previous year, the business earned $1.12 EPS. Medtronic PLC’s revenue was down 4.0% compared to the same quarter last year. equities analysts forecast that Medtronic PLC will post 4.77 earnings per share for the current year.
In other Medtronic PLC news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.02, for a total transaction of $1,264,320.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the transaction, the chief executive officer now owns 668,503 shares in the company, valued at approximately $54,569,899.89. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 172,407 shares of company stock worth $13,974,223. 0.31% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/medtronic-plc-mdt-position-reduced-by-castleark-management-llc/1723719.html.
Medtronic PLC Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.